Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Asep Medical Holdings Inc C.ASEP

Alternate Symbol(s):  SEPSF

ASEP Medical Holdings Inc. is a Canada-based company, which is in the business of acquiring research and development assets, technologies and/or businesses in the area of life sciences and medical diagnostics. The Company’s consolidates three development-stage companies, including Sepset Biosciences Inc., ABT Innovations Inc., and SafeCoat Medical Inc. It provides medical devices with an anti-microbial, antifouling coating through its SafeCoat Medical Inc. The Company provides diagnostic kits for predicting the onset of severe Sepsis and organ failure through its Sepset Biosciences Inc. The Company also offers peptide technology through its ABT Innovations Inc. and covers a range of therapeutic applications, including bacterial biofilm infections, anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants. SafeCoat Medical Inc.'s technology incorporates self-assembling biocompatible polymers combined with conjugated antimicrobial peptides.


CSE:ASEP - Post by User

Post by culturedpiggy01on Feb 04, 2022 4:27pm
76 Views
Post# 34399512

$ASEP.c licenses patent for AI-driven sepsis detection tech

$ASEP.c licenses patent for AI-driven sepsis detection tech

$ASEP.c just recently announced that they’ve finalized an exclusive licensing arrangement with UBC for a patented AI-driven sepsis diagnosis technology. The technology, developed under the direction of UBC microbiologist and the Company's Founding Director and COO, Dr. Robert E.W. Hancock, enables early and accurate diagnosis of the disease sepsis.

This could potentially revolutionize the detection of sepsis, which was estimated to cause 11 million deaths globally in 2017 and is also a major contributing factor in COVID-19 morbidity. this is big, following the development on this closely!

td, $ASEP.c trading at $0.37 with market cap at $20.77 M

 

<< Previous
Bullboard Posts
Next >>